Abstracts tagged "Autoantibody(ies)"

Abstract Number: 2021 • ACR Convergence 2022
Early Histopathological Changes of the Salivary Glands Associated with the Development of Primary Sjögren’s Syndrome
Xiaomei Shan¹, Clara Reichardt¹, Jeeshan Singh¹, Anne Zeitler², Christine Schauer¹, Jasmin Knopf¹, Martin Herrmann¹, Gerhard Grossmayer¹, Georg Schett¹ and Luis Munoz¹, ¹Universitätsklinikum Erlangen, Erlangen, Germany, ²Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany
Background/Purpose: Primary Sjögren's syndrome (PSS) is a chronic inflammatory disease affecting exocrine glands including salivary and lacrimal glands that leads to dry eyes and mouth…
Abstract Number: 0228 • ACR Convergence 2022
Are We Choosing Wisely? Results of a Survey of Internal Medicine Residents in a Single Center
Joel Wright and Dipal Patel, Englewood Health, Englewood, NJ
Background/Purpose: High value care must be prioritized given the rising costs associated with health care in the United States. The unwarranted testing of ANAs often…
Abstract Number: 0686 • ACR Convergence 2022
Anti-β2GP1/HLA-DR Antibody Is Associated with Arterial Thrombosis in Female Patients with Connective Tissue Diseases: A Cross-Sectional Study in Japan
Katsuhiko Yoneda¹, Yo Ueda¹, Kenji Tanimura², Hirotaka Yamada¹, Takaichi Okano³, Keisuke Nishimura¹, Hisashi Arase⁴, Hideto Yamada⁵ and Jun Saegusa¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Obstetrics and Gynecology, Kobe University Hospital, Kobe, Japan, ³Kobe University Hospital, Kobe, Japan, ⁴Department of Immunochemistry, Research Institute for Microbial Disease, Osaka University, Suita, Japan, ⁵Department of Obstetrics and Gynecology, Kobe University Hospital / Center for Recurrent Pregnancy Loss, Teine Keijinkai Hospital, Sapporo, Japan
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and/or pregnancy complications. Recently, β2-glycoprotein I (β2GPI) complexed with HLA class II molecules (β2GPI/HLA-DR)…
Abstract Number: 1121 • ACR Convergence 2022
Intricate Roles of Low Gene Copy Numbers for Complement C4, C4A Deficiency and HLA-DRB1*03 as Genetic Risk Factors for Myositis, Its Subgroups and Autoantibodies
Danlei Zhou¹, Emily H King¹, Simon Rothwell², Olga Kryštůfková³, Antonella Notarnicola⁴, Samantha Coss¹, Rabheh Abdul Aziz⁵, Katherine E Miller¹, Amanda Dang¹, G. Richard Yu¹, Joanne Drew⁶, Emeli Lundstrom⁴, Lauren Pachman⁷, Gulnara Mamyrova⁸, Rodolfo V Curiel⁸, Boel De Paepe⁹, Jan De Bleecker⁹, Antony Payton¹⁰, William Ollier¹¹, Terrance P O'Hanlon¹², Ira Targoff¹², Willy Flegel¹², Vidya Sivaraman⁶, Edward Oberle⁶, Shoghik Akoghlanian⁶, Kyla Driest⁶, Charles H Spencer¹³, Yee Ling Wu¹⁴, Haikady N Nagaraja¹⁵, Stacy P Ardoin⁶, Hector Chinoy¹⁶, Lisa G Rider¹², Frederick Miller¹², Ingrid Lundberg¹⁷, Leonid Padyukov¹⁸, Jiří Vencovský³, Janine A Lamb² and Chack-Yung Yu¹, ¹Center for Microbial Pathogenesis, Abigail Wexner Research Institute, Nationwide Children’s Hospital, Columbus, OH, ²National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁶Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁷Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL, ⁸Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁹Department of Neurology, Ghent University Hospital, Ghent, Belgium, ¹⁰Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, ¹¹Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom, ¹²Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ¹³Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, MS, ¹⁴Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, ¹⁵Division of Biostatistics, The Ohio State University, Columbus, OH, ¹⁶The University of Manchester, Sale, United Kingdom, ¹⁷Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ¹⁸Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by autoantibodies plus infiltration of leukocytes into muscles and/or the skin, leading to…
Abstract Number: 1542 • ACR Convergence 2022
Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry
Shery Susan Philip¹, Ramya Janardana¹, Revanesh S Mirji¹, Chengappa Kavadichanda², Devender Bairwa³, Geetabali Sircar⁴, Parasar Ghosh⁵, Anupam Wakhlu⁶, Padmanabha Shenoy⁷, Sumithra Selvam⁸ and Vineeta Shobha¹, ¹St. John’s Medical College Hospital, Bangalore, India, ²JIPMER, Pondicherry, Puducherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, ⁴Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India, ⁵Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁶Apollo Medics Super Speciality Hospitals, Lucknow, India, ⁷Centre for Arthritis and Rheumatism Excellence (CARE), Cochi, India, ⁸Division of Epidemiology and Biostatistics, St. John’s Research Institute, St. John's Medical College Hospital, Bangalore, India
Background/Purpose: Classification of systemic sclerosis (SSc) into subsets has been a challenge due to it's heterogeneity. This study attempts to identify SSc subsets based on…
Abstract Number: 2023 • ACR Convergence 2022
Salivary Autoantibodies in Sicca Patients Are Associated with Dry Symptoms
Martha Tsaliki¹, Joshua Cavett¹, Biji T. Kurien², Christina Bruxvoort¹, Robert Hal Scofield² and Kristi A Koelsch³, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Sjögren’s Syndrome (SS) diagnosis depends on clinic examinations that involve measurements of serum levels of anti-Ro\SSA, anti-La\SSB, and rheumatoid factor antibodies; the first is…
Abstract Number: 0321 • ACR Convergence 2022
M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort
Eugene Krustev¹, John Hanly², Ricky Chin³, Katherine Buhler¹, Francesca S Cardwell⁴, Murray Urowitz⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Jorge Sanchez-Guerrero⁹, Sasha Bernatsky¹⁰, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul R Fortin¹⁵, Dafna Gladman¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen M. Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald van Vollenhoven²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat İnanç²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Jill Buyon³⁵, Marvin Fritzler¹, Ann E Clarke³⁶ and May Choi³⁷, ¹University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ³University of Calgary, Ottawa, ON, Canada, ⁴University of Waterloo, Department of Geography & Environmental Management, Burlington, ON, Canada, ⁵University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, Republic of Korea, ⁸Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁹Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²University College London, London, United Kingdom, ¹³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, ¹⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁷Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ²²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²³Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, ²⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University Faculty of Medicine, Istanbul, Turkey, ³⁰University of California San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Charleston, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵NYU Grossman School of Medicine, New York, NY, ³⁶University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ³⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: We previously reported in a single centre prevalent SLE cohort that antibodies against the cytokinesis-associated protein M-Phase Phosphoprotein 1 (anti-MPP-1) were associated with SLE-related…
Abstract Number: 0691 • ACR Convergence 2022
Structural Differences Exist in Beta-2-Glycoprotein I from APS Patients Compared to Healthy Controls
Hannah Britt¹, Hannah Bradford¹, Valentina Spiteri¹, Anisur Rahman², Ian Giles¹, Mihaela Delcea³, Paul Dalby¹, Kostas Thalassinos¹ and Thomas McDonnell¹, ¹University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³University of Greifswald, Greifswald, Germany
Background/Purpose: Beta-2-Glycoprotein I (B2GPI) is a serum protein of approximately 50kDa and is the main autoantigen of Antiphospholipid syndrome (APS). Antibodies to B2GPI (aB2GPI) are…
Abstract Number: 1141 • ACR Convergence 2022
Consequences of SLE Heterogeneity on the Epigenome and the Drivers Behind
Olivia Castellini-Pérez¹, Athina Spiliopoulou², Guillermo Barturen¹, Andrii Iakovliev², Manuel Martinez-Bueno¹, Elena Carnero-Montoro¹ and Marta Alarcon-Riquelme¹, ¹Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²University of Edinburgh, Edinburgh, Scotland, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a prototypic systemic autoimmune disease characterized by a complex aetiology and heterogenous symptomatology which has been recently dissected using…
Abstract Number: 1629 • ACR Convergence 2022
AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases
Shawn Morales, Jennifer Cross and Robert Huizinga, Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada
Background/Purpose: AUR200 targets both B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are key mediators in the pathogenesis of B cell-mediated autoimmune…
Abstract Number: 2024 • ACR Convergence 2022
Salivary Gland Ultrasound May Lead to a More Accurate Stratification of Patients with the Same Serological Profile in Sjögren’s Syndrome: Towards a Personalized Approach
Silvia Fonzetti¹, Francesco Ferro², Gaetano La Rocca³, Giovanni Fulvio⁴, Inmaculada Concepción Navarro García⁵, Gianmaria Governato⁶, Valentina Donati⁷, Marta Mosca⁸ and Chiara Baldini⁴, ¹Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, ⁴University of Pisa, Pisa, Pisa, Italy, ⁵Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶Azienda Ospedaliera Universitaria Pisana, Pisa, Pisa, Italy, ⁷Pathology Unit, University of Pisa, Pisa, Italy, ⁸Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Salivary gland ultrasound (SGUS) abnormalities have been increasingly recognized as possible biomarkers for Sjögren's Syndrome (SS) phenotypic stratification. However, to date few studies have…
Abstract Number: 0326 • ACR Convergence 2022
Mapping Anti-Mitochondrial Antibodies over Time in a Lupus Inception Cohort
Yann Becker¹, Éric Boilard¹, Emmanuelle Rollet-Labelle¹, Christian Lood², Anne-Sophie Julien³, Joannie Leclerc¹, Tania Lévesque¹, Murray Urowitz⁴, John Hanly⁵, Caroline Gordon⁶, Sang-Cheol Bae⁷, Juanita Romero-Diaz⁸, Jorge Sanchez-Guerrero⁹, Ann E Clarke¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Dafna Gladman¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen M. Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald van Vollenhoven²⁵, Cynthia Aranow²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat Inanc²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Jill Buyon³⁵ and Paul R Fortin³⁶, ¹Centre de Recherche ARThrite, CHU de Québec - Université Laval, Québec, QC, Canada, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Université Laval, Québec, QC, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁵Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Hanyang University Medical Center, Seoul, Republic of Korea, ⁸Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁹Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ¹¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹²Cedars-Sinai Medical Center, Los Angeles, CA, ¹³University College London, London, United Kingdom, ¹⁴Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁷Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ²²Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²³Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, ²⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, ³⁰University of California San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Charleston, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵NYU Grossman School of Medicine, New York, NY, ³⁶Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada
Background/Purpose: Mitochondria can be both pro-inflammatory and antigenic. We hypothesize (1) that anti-mitochondrial antibodies (AMA) are present in lupus and (2) can predict outcomes. Our…
Abstract Number: 0694 • ACR Convergence 2022
Evaluation of the Effect of UCB4470 (anti-mouse FcRn) on Amelioration of Thrombosis in a Mouse Model of Antiphospholipid (aPL)-induced Thrombosis
Maria Laura Bertolaccini¹, Yiannis Ioannou², Helen Neale³, Prakash Saha¹ and Alberto Smith¹, ¹King's College London, London, United Kingdom, ²UCB Biopharma SRL, London, United Kingdom, ³UCB Biopharma SRL, Slough, United Kingdom
Background/Purpose: FcRn (the neonatal Fc receptor) is a receptor expressed by antigen-presenting cells, such as monocytes, macrophages, and dendritic cells, as well as on neutrophils.…
Abstract Number: 1161 • ACR Convergence 2022
IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis
Marie-Christin Hoffmann¹, Natalie Fadle¹, Evi Regitz¹, Klaus-Dieter Preuss¹, Marina Zaks², Elisabeth Stöger³, Vincent Zimmer⁴, Philipp Klemm⁵, Gunter Assmann⁶, Bernhard Thurner⁷, Claudia Pföhler⁸, Joerg Thomas Bittenbring¹, Christoph Kessel⁹ and Lorenz Thurner¹, ¹José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany, ²Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany, ³Evangelische Kliniken Essen-Mitte gGmbH, Evangelische Huyssens-Stiftung Essen-Huttrop, Essen, Germany, Essen, Germany, ⁴Department of Medicine, Knappschaftsklinikum Saar, Püttlingen, Germany, Department of Medicine II, Saarland University Medical School, Homburg/Saar, Germany, ⁵Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, ⁶Klinik für Rheumatologie und klinische Immunologie, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Minden, Germany, Minden, Germany, ⁷Department of Pediatrics, Klinikum Kempten, Kempten, Germany, ⁸Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany, ⁹Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany, Münster, Germany
Background/Purpose: Psoriasis arthritis is known as a subtype of seronegative spondylarthritis. However, autoantibodies against the receptor antagonist at tumor necrosis factor receptor 1 and 2…
Abstract Number: 1632 • ACR Convergence 2022
Novel Autoantibodies Identify Sjögren’s Disease in Patients Lacking Serum IgG Specific for Ro/SS-A and La/SS-B
Sherri Longobardi¹, Charmaine Lopez-Davis¹, Bhuwan Khatri¹, Constantin Georgescu¹, Christina Lawrence¹, Astrid Rasmussen¹, Lida Radfar², R. Hal Scofield², Robert C. Axtell¹, Gabriel Pardo¹, Jonathan Wren¹, Kristi A Koelsch¹, Joel Guthridge¹, Judith James¹, Christopher Lessard¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Classification of Sjögren's disease (SjD) requires either Ro/SS-A autoantibodies or minor salivary gland biopsy positive for focal lymphocytic infiltrates. Up to 40% of SjD…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].